You are here

High-throughput cell-free production of human genetic variants

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43HG011602-01
Agency Tracking Number: R43HG011602
Amount: $252,116.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NHGRI
Solicitation Number: PA19-272
Timeline
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-09-11
Award End Date (Contract End Date): 2021-03-31
Small Business Information
953 INDIANA ST
San Francisco, CA 94107-3007
United States
DUNS: 079761816
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 KELLY TREGO
 (510) 486-7143
 kstrego@lbl.gov
Business Contact
 ZACHARY SUN
Phone: (646) 725-6686
Email: zach@synvitrobio.com
Research Institution
N/A
Abstract

Project Summary
The rapidly evolving field of human functional genomics has created the promise of personalized medicine. While
extensive sequencing has generated valuable genetic association data, our ability to test linked variants in
disease has not kept pace. As a result, most Single Nucleotide Polymorphisms (SNPs) are classified as Variants
of Unknown Significance (VUS). Following up on function is essential to determine the causal variants and genes
for disease biology and drug discovery. There are currently no technologies to produce variants en masse from
genomic association data to establish function. We propose using Synvitrobio’s cell-free protein expression and
purification platform to rapidly express and purify human SNP variants for downstream functional testing. Cell-
free systems take only 8 hours to express, rather than days to weeks in cells, since there is no need for cloning
and transformation. They are also at least 10-fold cheaper to run than cells, can be run in high-throughput as
reactions (384 well plates), and can be scaled up for protein purification. In short, our approach provides a
scalable alternative to cell-based heterologous expression. This Phase I study proposes to produce model
human SNP variants using traditional in cellulo methods and compare the specific activity to proteins produced
via Synvitrobio’s cell-free platform. We propose two aims that de-risk the strategy of constructing panels of
human SNP variants using high-throughput cell-free tools. Aim 1 focuses on a class of protein known to express
in E. coli systems, whereas the protein class in Aim 2 is more challenging in typical prokaryotic expression
systems. Building a toolbox for variant expression and purification would facilitate understanding the causal
variants and genes for disease biology and drug discovery.Project Narrative
A high-throughput, cell-free expression tool capable of expressing genetic variants of human coding
sequences benefits the public by allowing the exponentially increasing amounts of personal and human
genomics data to be interpreted and understood through protein variant production and characterization. This
leads to a better understanding of human pathophysiology, the relationship between genotype and phenotype,
and ultimately novel and personalized therapeutics.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government